The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis.

Xiaoling CaiWenjia YangXueying GaoYifei ChenLingli ZhouSimin ZhangXueyao HanXiantong Zou

Published in: Obesity (Silver Spring, Md.) (2017)

Body weight significantly decreased in patients with type 2 diabetes who received different dosages of SGLT2 inhibitors compared with patients who received a placebo. Moreover, in patients treated with dapagliflozin, there was a statistically significant dosage-dependent trend in body weight reduction.

Keyphrases

body weight
type diabetes
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
cardiovascular disease
prognostic factors
clinical trial
insulin resistance
physical activity
metabolic syndrome
adipose tissue
weight loss
double blind
open label